EX-99.1 2 tomz_ex991.htm PRESS RELEASE tomz_ex991.htm

EXHIBIT 99.1

 

 

TOMI ENVIRONMENTAL SOLUTIONS, INC. REPORTS FIRST QUARTER 2025 RESULTS

 

FREDERICK, MD, May 8, 2025 — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its financial results for the first quarter ended March 31, 2025.

 

TOMI Chief Executive Officer, Dr. Halden Shane, stated, “The first quarter of 2025 delivered improved financial results as we grew quarter-over-quarter revenue by 42% and continue to see positive trends in the market with demand for our product lines and recurring solution sales.  The increase in revenue, consistent gross profit and lower operating expenses all contributed to improved financial results for the first quarter of 2025, when compared to the same prior year period.

 

“We are off to a strong start thus far in 2025 and we expect to see similar trends for the remainder of 2025 and will continue to focus on executing our strategies to grow revenues, expand business development and deliver improved results and value for our shareholders,” Dr. Shane concluded.

 

Financial Results for the three months ended March 31, 2025, compared to March 31, 2024

 

 

·

Sales, net was $1,577,000 compared to $1,114,000 for the three months ended March 31, 2025 and 2024, respectively.

 

 

 

 

·

Gross margin was 60.4% compared to 60.2% in the prior year period.

 

 

 

 

·

Operating loss was $(754,000), compared to $(1,226,000) in the prior year period.

 

 

 

 

·

Net loss was $(256,000) or $(0.01) per basic and diluted share, compared to $(1,310,000) or $(0.07) per basic and diluted share in the same period last year.

 

Recent Business Highlights:  

 

 

·

SteraMist product-based revenues for the three months ended March 31, 2025 and 2024, were $1,000,000 and $743,000, respectively, representing an increase of $257,000 when compared to the same prior year period. The higher revenue was attributable to increased demand for our SteraMist BIT solution, mobile handheld point and spray product lines, the SteraMist Integrated System (SIS) product offering, scope adjustments to align with client needs and project dynamics on currently installed Custom Engineered Systems (CES’s) among deliverables to new projects.

 

·

197% quarter over quarter growth in SteraMist BIT solution sales for the first quarter of 2025, compared to the same prior year period.

 

·

Service-based revenue for the three months ended March 31, 2025 and 2024, was $577,000 and $371,000, respectively, representing a year over year increase of $206,000, or 56%. The increase in service revenue was due to increased demand for iHP services as well as expanded services offered by the company.

 

·

Domestic revenue for the three months ended March 31, 2025 and 2024 was $1,192,000 and $662,000, respectively, an increase of $530,000 or 80%, when compared to the same prior year period. Domestic revenue increased due to higher demand for our solution, mobile equipment, CES and iHP service sales.

 

·

Sales backlog at March 31, 2025 was $1,225,000, representing an increase of $348,000 over the reported amount at December 31, 2024.

 

·

In March 2025, the Company announced a significant contract to install a SteraMist iHP Custom Engineered System (CES) at a leading university in Rhode Island, valued at approximately $450,000. This new client was secured through distributor ARES Distribution, and underscores TOMI’s competitive advantage, having successfully outperformed key hydrogen peroxide competitors.

 

 
1

 

 

 

·

The Company announced in March the deployment of SteraMist iHP technology at the NASA Johnson Space Center, marking the Company’s expansion into the aerospace sector, showcasing its potential for broader applications within the aerospace sector and beyond. This strategic partnership aligns with the Company’s ongoing SteraMistX campaign, which focuses on aerospace, military, and exploration fields utilizing iHP decontamination to elevate biosecurity biosafety standards.

 

·

In March 2025, TOMI announced an OEM partnership with Pharma Biotech System Components LLC/Pharma Biotech System Components Ltd (PBSC), a premier manufacturer specializing in high containment, material decontamination, and cleanroom solutions. This collaboration enhances TOMI's SteraMist Integrated System (SIS) product launched in the second half of last year. Through this OEM agreement, TOMI will now offer pass-through hatches and chambers integrated with iHP, specifically designed for optimized decontamination cycles.

 

·

On March 21, 2025, the Company announced the expansion into Aquaculture with new partner, Algafeed

 

Conference Call Information

 

TOMI will hold a conference call to discuss First Quarter 2025 results at 4:30 p.m. ET today, May 8, 2025.

 

To participate in the call by phone, dial (877) 545-0320 approximately five minutes prior to the scheduled start time and provide participant access code 616069, or request the "TOMI Environmental Solutions first quarter earnings call." International callers please dial (973) 528-0002. To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link: https://www.webcaster4.com/Webcast/Page/2262/52458.

 

A replay of the teleconference will be available until Thursday, May 22, 2025, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use replay access code: 52458. A replay of the webcast will be available for at least 90 days on the company’s website, starting approximately one hour after the completion of the call.

 

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

 

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.

 

TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.

 

TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.

 

For additional information, please visit https://www.steramist.com or contact us at [email protected].

 

Forward-Looking Statements

 

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation,  our strategies to grow revenue and expand business development, our expectation with respect to the remainder of 2025; our ability to generate lead and referral for sales, and our ability to improve financial performance. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

 

 
2

 

 

The following represents our consolidated balance sheets and statement of operations from our recently filed Form 10-Q:

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 CONDENSED CONSOLIDATED BALANCE SHEETS

 

ASSETS

Current Assets:

 

 

 

 

 

 

 

 

March 31,

2025 (Unaudited)

 

 

December 31,

2024

 

Cash and Cash Equivalents

 

$ 674,181

 

 

$ 664,879

 

Accounts Receivable – net

 

 

1,930,196

 

 

 

1,881,138

 

Other Receivables

 

 

455,010

 

 

 

-

 

Inventories, net

 

 

3,405,710

 

 

 

3,578,202

 

Vendor Deposits

 

 

32,915

 

 

 

35,895

 

Prepaid Expenses

 

 

281,480

 

 

 

332,999

 

Total Current Assets

 

 

6,779,492

 

 

 

6,493,113

 

 

 

 

 

 

 

 

 

 

Property and Equipment – net

 

 

818,304

 

 

 

875,449

 

 

 

 

 

 

 

 

 

 

Other Assets:

 

 

 

 

 

 

 

 

Intangible Assets – net

 

 

1,243,776

 

 

 

1,250,574

 

Operating Lease - Right of Use Asset

 

 

380,791

 

 

 

399,254

 

Other Assets

 

 

735,414

 

 

 

675,348

 

Total Other Assets

 

 

2,359,981

 

 

 

2,325,176

 

Total Assets

 

$ 9,957,777

 

 

$ 9,693,738

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts Payable

 

$ 1,767,896

 

 

$ 1,924,379

 

Accrued Expenses and Other Current Liabilities

 

 

878,084

 

 

 

455,675

 

Deferred Revenue

 

 

233,727

 

 

 

211,724

 

Current Portion of Long-Term Operating Lease

 

 

132,660

 

 

 

129,132

 

Total Current Liabilities

 

 

3,012,367

 

 

 

2,720,910

 

 

 

 

 

 

 

 

 

 

Long-Term Liabilities:

 

 

 

 

 

 

 

 

Long-Term Operating Lease, Net of Current Portion

 

 

479,357

 

 

 

513,395

 

Convertible Notes Payable, net of unamortized debt discount of $262,293 and $239,506 at March 31, 2025 and December 31, 2024, respectively

 

 

2,622,707

 

 

 

2,360,494

 

Total Long-Term Liabilities

 

 

3,102,064

 

 

 

2,873,889

 

Total Liabilities

 

 

6,114,431

 

 

 

5,594,799

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Shareholders’ Equity:

 

 

 

 

 

 

 

 

Cumulative Convertible Series A Preferred Stock; par value $0.01 per share, 1,000,000 shares authorized; 63,750 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

 

 

638

 

 

 

638

 

Cumulative Convertible Series B Preferred Stock; $1,000 stated value; 7.5% Cumulative dividend; 4,000 shares authorized; none issued and outstanding at March 31, 2025 and December 31, 2024, respectively

 

 

-

 

 

 

-

 

Common stock; par value $0.01 per share, 250,000,000 shares authorized; 20,015,205 and 20,015,205 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

 

 

200,152

 

 

 

200,152

 

Additional Paid-In Capital

 

 

58,201,140

 

 

 

58,201,140

 

Accumulated Deficit

 

 

(54,558,584 )

 

 

(54,302,991 )

Total Shareholders’ Equity

 

 

3,843,346

 

 

 

4,098,939

 

Total Liabilities and Shareholders’ Equity

 

$ 9,957,777

 

 

$ 9,693,738

 

 

 
3

 

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

For The Three Months Ended

 

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Sales, net

 

$ 1,576,558

 

 

$ 1,114,087

 

Cost of Sales

 

 

624,813

 

 

 

443,419

 

Gross Profit

 

 

951,745

 

 

 

670,668

 

 

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

Professional Fees

 

 

219,316

 

 

 

197,999

 

Depreciation and Amortization

 

 

68,542

 

 

 

77,921

 

Selling Expenses

 

 

246,406

 

 

 

289,069

 

Research and Development

 

 

44,580

 

 

 

67,971

 

Consulting Fees

 

 

102,766

 

 

 

113,635

 

General and Administrative

 

 

1,024,600

 

 

 

1,150,549

 

Total Operating Expenses

 

 

1,706,210

 

 

 

1,897,144

 

Income (loss) from Operations

 

 

(754,465 )

 

 

(1,226,476 )

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

Other Income

 

 

534,912

 

 

 

-

 

Interest Income

 

 

82,890

 

 

 

9,906

 

Interest Expense

 

 

(118,930 )

 

 

(93,620 )

Total Other Income (Expense)

 

 

498,872

 

 

 

(83,714 )

 

 

 

 

 

 

 

 

 

Income (loss) before income taxes

 

 

(255,593 )

 

 

(1,310,190 )

Provision for Income Taxes

 

 

-

 

 

 

-

 

Net Income (loss)

 

$ (255,593 )

 

$ (1,310,190 )

 

 

 

 

 

 

 

 

 

Net income (loss) Per Common Share

 

 

 

 

 

 

 

 

Basic

 

$ (0.01 )

 

$ (0.07 )

Diluted

 

$ (0.01 )

 

$ (0.07 )

 

 

 

 

 

 

 

 

 

Basic Weighted Average Common Shares Outstanding

 

 

20,015,205

 

 

 

19,954,511

 

Diluted Weighted Average Common Shares Outstanding

 

 

20,015,205

 

 

 

19,954,511

 

 

 
4

 

 

INVESTOR RELATIONS CONTACT:

John Nesbett/Rosalyn Christian

IMS Investor Relations

[email protected]

 

 
5